Gender differences in drug responses

Pharmacological Research

Volumn 55, Issue 2, 2007, Pages 81-95

  Franconi, Flavia ^a   Brunelleschi, Sandra ^b   Steardo, Luca ^c   Cuomo, Vincenzo ^c  

^a UNIVERSITY OF SASSARI   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Drug response; Gender differences (GDs); Pharmacodynamics; Pharmacokinetics

Indexed keywords

ACETYLSALICYLIC ACID; ANOREXIGENIC AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CLOZAPINE; CYCLOSPORIN; DEXTROMETHORPHAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROMYCIN; FLUPHENAZINE; HISTAMINE H1 RECEPTOR ANTAGONIST; IBUTILIDE; MIDAZOLAM; NEUROLEPTIC AGENT; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; PLACEBO; RILUZOLE; SPARTEINE; THEOPHYLLINE; TIRILAZAD; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

BLOOD DYSCRASIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COUGHING; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENERGY METABOLISM; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOKALEMIA; HYPONATREMIA; IMMUNE SYSTEM; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK FACTOR; SEX DIFFERENCE; SEXUAL DYSFUNCTION; URINARY EXCRETION; VALVULAR HEART DISEASE;

CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; ENERGY METABOLISM; FEMALE; HUMANS; MALE; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY; RISK FACTORS; SEX CHARACTERISTICS;

EID: 33846642215     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2006.11.001     Document Type: Review

References (246)

1. Legato M.J. Principles of gender-specific medicine. 1st ed. (2004), Elsevier Academic Press, San Diego p. 1396
2. Tran C., Knowles S.R., Liu B.A., and Shear N.H. Gender differences in adverse drug reactions. J Clin Pharmacol 38 (1998) 1003-1009
3. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther 24 (1999) 339-346
4. Chen M.L., Lee S.C., Ng M.J., Schuirmann D.J., Lesko L.J., and Williams R.L. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther 68 (2000) 510-517
5. Tannenbaum G.S., Choi H.K., Gurd W., and Waxman D.J. Temporal relationship between the sexually dimorphic spontaneous GH secretory profiles and hepatic STAT5 activity. Endocrinology 142 (2001) 4599-4606
6. Gandhi M., Aweeka F., Greenblatt R.M., and Blaschke T.F. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 44 (2004) 499-523
7. Schwartz J.B. The influence of sex on pharmacokinetics. Clin Pharmacokinet 42 (2003) 107-121
8. Anderson G.D. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health (Larchmt) 14 (2005) 19-29
9. Kashuba A.D., and Nafziger A.N. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet 34 (1998) 203-218
10. Karceski S., and Morrell M.J. Women with epilepsy: current treatment strategies. J Gend Specif Med 5 (2002) 22-26
11. Tamminga W.J., Wemer J., Oosterhuis B., Wieling J., Wilffert B., de Leij L.F., et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 55 (1999) 177-184
12. Burgoyne P.S. A Y chromosomal effect on blastocyst number in mice. Development 117 (1993) 341-345
13. Nagy E., Orvos H., Bardos G., and Molnar P. Gender-related heart rate differences in human neonates. Pediatr Res 47 (2000) 778-780
14. Webster-Gandy J., Warren J., and Henry C.J. Sexual dimorphism in fat patterning in a sample of 5 to 7-year-old children in Oxford. Int J Food Sci Nutr 54 (2003) 467-471
15. Strolin Benedetti M., and Baltes E.L. Drug metabolism and disposition in children. Fundam Clin Pharmacol 17 (2003) 281-299
16. Nakamura K., Fujiki T., and Tamura H.O. Age, gender and region-specific differences in drug metabolising enzymes in rat ocular tissues. Exp Eye Res 81 (2005) 710-715
17. Carrel L., Cottle A.A., Goglin K.C., and Willard H.F. A first-generation X-inactivation profile of the human X chromosome. Proc Natl Acad Sci USA 96 (1999) 14440-14444
18. Carrel L., and Willard H.F. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature 434 (2005) 400-404
19. Regitz-Zagrosek V. Therapeutic implications of gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov 5 (2006) 425-438
20. Costa L.G., Steardo L., and Cuomo V. Structural effects and neurofunctional sequelae of developmental exposure to psychotherapeutic drugs: experimental and clinical aspects. Pharmacol Rev 56 (2004) 103-147
21. Weitam S., Ochoa S., Sullivan J., Shuster J., Winick N., Pratt C., et al. Pediatric Phase II cancer chemiotherapy trials: a pediatric oncology group study. J Pediatr Hematol Oncol 19 (1997) 187-191
22. Sanchez-Borges M., Capriles-Behrens E., and Caballero-Fonseca F. Hypersensitivity to non-steroidal anti-inflammatory drugs in childhood. Pediatr Allergy Immunol 15 (2004) 376-380
23. Beecher H.K. The powerful of placebo. J Am Med Assoc 159 (1955) 1602-1606
24. Benson H. The nocebo effect: history and physiology. Prev Med 26 (1997) 612-615
25. Rickels K. Some comments on non-drug factors in psychiatric drug therapy. Psychosomatics 6 (1965) 303-309
26. Wilcox C.S., Cohn J.B., Linden R.D., Heiser J.F., Lucas P.B., Morgan D.L., et al. Predictors of placebo response: a retrospective analysis. Psychopharmacol Bull 28 (1992) 157-162
27. Compton P., Charuvastra V.C., and Ling W. Effect of oral ketorolac and gender on human cold pressor pain tolerance. Clin Exp Pharmacol Physiol 30 (2003) 759-763
28. Saxon L., Hiltunen A.J., Hjemdahl P., and Borg S. Gender-related differences in response to placebo in benzodiazepine withdrawal: a single-blind pilot study. Psychopharmacology (Berl) 153 (2001) 231-237
29. Pud D., Yarnitsky D., Sprecher E., Rogowski Z., Adler R., and Eisenberg E. Can personality traits and gender predict the response to morphine? An experimental cold pain study. Eur J Pain 10 (2006) 103-112
30. Gear R.W., Miaskowski C., Gordon N.C., Paul S.M., Heller P.H., and Levine J.D. The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain 83 (1999) 339-345
31. Averbuch M., and Katzper M. Gender and the placebo analgesic effect in acute pain. Clin Pharmacol Ther 70 (2001) 287-291
32. Mencke T., Schreiber J.U., Knoll H., Stracke C., Kleinschmidt S., Rensing H., et al. Women report more pain on injection of a precurarization dose of rocuronium: a randomized, prospective, placebo-controlled trial. Acta Aneasthesiol Scand 48 (2004) 1245-1248
33. Olofsen E., Romberg R., Bijl H., Mooren R., Engbers F., Kest B., et al. Alfentanil and placebo analgesia: no sex differences detected in models of experimental pain. Anesthesiology 103 (2005) 130-139
34. Eccles R. Mechanisms of the placebo effect of sweet cough syrups. Respir Physiol Neurobiol 152 (2006) 340-348
35. Harris R.Z., Benet L.Z., and Schwartz J.B. Gender effect in pharmacokinetics and pharmacodynamics. Drugs 50 (1995) 222-239
36. Anthony M., and Berg M.J. Biological and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics and pharmacogenetics. Part II. J Womens Health Gend Based Med 11 (2002) 617-629
37. Hutson W.R., Roehrkasse R.L., and Wald A. Influence of gender and menopause on gastric emptying and motility. Gastroenterology 96 (1989) 11-17
38. Singer A.J., and Brandt L.J. Pathophysiology of the gastrointestinal tract during pregnancy. Am J Gastroenterol 86 (1991) 1695-1712
39. Sadik R., Abrahamsson H., and Stotzer P.O. Gender differences in gut transit shown with a newly developed radiological procedure. Scand J Gastroenterol 38 (2003) 36-42
40. Mearadji B., Penning C., Vu M.K., van der Schaar P.J., van Petersen A.S., Kamerling I.M., et al. Influence of gender on proximal gastric motor and sensory function. Am J Gastroenterol 96 (2001) 2066-2073
41. Frezza M., di Padova C., Pozzato G., Terpin M., Baraona E., and Lieber C.S. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med 322 (1990) 95-99
42. Gorski J.C., Jones D.R., Haehner-Daniels B.D., Hamman M.A., O'Mara Jr. E.M., and Hall S.D. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 64 (1998) 133-143
43. Krecic-Shepard M.E., Barnas C.R., Slimko J., Jones M.P., and Schwartz J.B. Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J Clin Pharmacol 40 (2000) 219-230
44. Schuetz E.G., Furuya K.N., and Schuetz J.D. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 275 (1995) 1011-1018
45. Kim R.B., Leake B.F., Choo E.F., Dresser G.K., Kubba S.V., Schwarz U.I., et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70 (2001) 189-199
46. Wedel M., Pieters J.E., Pikaar N.A., and Ockhuizen T. Application of a three-compartment model to a study of the effects of sex, alcohol dose and concentration, exercise and food consumption on the pharmacokinetics of ethanol in healthy volunteers. Alcohol Alcohol 26 (1991) 329-336
47. Ochs H.R., Greenblatt D.J., Divoll M., Abernethy D.R., Feyerabend H., and Dengler H.J. Diazepam kinetics in relation to age and sex. Pharmacology 23 (1981) 24-30
48. Greenblatt D.J., Allen M.D., Harmatz J.S., and Shader R.I. Diazepam disposition determinants. Clin Pharmacol Ther 27 (1980) 301-312
49. Xue F.S., Tong S.Y., Liao X., Liu J.H., An G., and Luo L.K. Dose-response and time course of effect of rocuronium in male and female anesthetized patients. Anesth Analg 85 (1997) 667-671
50. Xue F.S., An G., Liao X., Zou Q., and Luo L.K. The pharmacokinetics of vecuronium in male and female patients. Anesth Analg 86 (1998) 1322-1327
51. Succari M., Foglietti M.J., and Percheron F. Microheterogeneity of alpha 1-acid glycoprotein: variation during the menstrual cycle in healthy women, and profile in women receiving estrogen-progestogen treatment. Clin Chim Acta 187 (1990) 235-241
52. Tuck C.H., Holleran S., and Berglund L. Hormonal regulation of lipoprotein(a) levels: effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women. Arterioscler Thromb Vasc Biol 17 (1997) 1822-1829
53. Brinkman-Van der Linden C.M., Havenaar E.C., Van Ommen C.R., Van Kamp G.J., Gooren L.J., and Van Dijk W. Oral estrogen treatment induces a decrease in expression of sialyl Lewis x on alpha 1-acid glycoprotein in females and male-to-female transsexuals. Glycobiology 6 (1996) 407-412
54. Rowland M., and Tozer T.N. Clinical pharmacokinetics: concepts and applications. 3rd ed. (1995), Lippincott Williams & Wilkins, Philadelphia p. 601
55. Wilson K. Sex-related differences in drug disposition in man. Clin Pharmacokinet 9 (1984) 189-202
56. Smith G., Stubbins M.J., Harries L.W., and Wolf C.R. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica 28 (1998) 1129-1165
57. Ou-Yang D.S., Huang S.L., Wang W., Xie H.G., Xu Z.H., Shu Y., et al. Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br J Clin Pharmacol 49 (2000) 145-151
58. Nafziger A.N., and Bertino Jr. J.S. Sex-related differences in theophylline pharmacokinetics. Eur J Clin Pharmacol 37 (1989) 97-100
59. Ereshefsky L., Saklad S.R., Watanabe M.D., Davis C.M., and Jann M.W. Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. J Clin Psychopharmacol 11 (1991) 296-301
60. Bruno R., Vivier N., Montay G., Le Liboux A., Powe L.K., Delumeau J.C., et al. Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. Clin Pharmacol Ther 62 (1997) 518-526
61. Kalow W., and Tang B.K. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 50 (1991) 508-519
62. Miners J.O., Attwood J., and Birkett D.J. Influence of sex and oral contraceptive steroids on paracetamol metabolism. Br J Clin Pharmacol 16 (1983) 503-509
63. Kaye C.M., and Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 39 (2000) 243-254
64. Guengerich F.P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39 (1999) 1-17
65. Meibohm B., Beierle I., and Derendorf H. How important are gender differences in pharmacokinetics?. Clin Pharmacokinet 41 (2002) 329-342
66. Kahan B.D., Kramer W.G., Wideman C., Flechner S.M., Lorber M.I., and Van Buren C.T. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation 41 (1986) 459-464
67. Austin K.L., Mather L.E., Philpot C.R., and McDonald P.J. Intersubject and dose-related variability after intravenous administration of erythromycin. Br J Clin Pharmacol 10 (1980) 273-279
68. Hulst L.K., Fleishaker J.C., Peters G.R., Harry J.D., Wright D.M., and Ward P. Effect of age and gender on tirilazad pharmacokinetics in humans. Clin Pharmacol Ther 55 (1994) 378-384
69. Dilger K., Eckhardt K., Hofmann U., Kucher K., Mikus G., and Eichelbaum M. Chronopharmacology of intravenous and oral modified release verapamil. Br J Clin Pharmacol 47 (1999) 413-419
70. Krecic-Shepard M.E., Park K., Barnas C., Slimko J., Kerwin D.R., and Schwartz J.B. Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther 68 (2000) 130-142
71. Lemmens H.J., Burm A.G., Hennis P.J., Gladines M.P., and Bovill J.G. Influence of age on the pharmacokinetics of alfentanil. Gender dependence. Clin Pharmacokinet 19 (1990) 416-422
72. Hunt C.M., Westerkam W.R., and Stave G.M. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 44 (1992) 275-283
73. Schmidt R., Baumann F., Hanschmann H., Geissler F., and Preiss R. Gender difference in ifosfamide metabolism by human liver microsomes. Eur J Drug Metab Pharmacokinet 26 (2001) 193-200
74. Cummins C.L., Wu C.Y., and Benet L.Z. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 72 (2002) 474-489
75. Lan L.B., Dalton J.T., and Schuetz E.G. Mdr1 limits CYP3A metabolism in vivo. Mol Pharmacol 58 (2000) 863-869
76. Tang W., and Stearns R.A. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr Drug Metab 2 (2001) 185-198
77. Wenk M., Todesco L., and Krahenbuhl S. Effect of St. John's worth on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol 57 (2004) 495-499
78. Tanaka E. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharm Ther 23 (1998) 403-416
79. May D.G., Porter J., Wilkinson G.R., and Branch R.A. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin Pharmacol Ther 55 (1994) 492-500
80. Labbe L., Sirois C., Pilote S., Arseneault M., Robitaille N.M., Turgeon J., et al. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 10 (2000) 425-438
81. Ronfeld R.A., Tremaine L.M., and Wilner K.D. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 32 (1997) 22-30
82. Abernethy D.R., Greenblatt D.J., and Shader R.I. Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther 232 (1985) 183-188
83. Timmer C.J., Sitsen J.M., and Delbressine L.P. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 38 (2000) 461-474
84. Lam L.C., Garcia-Barcelo M.M., Ungvari G.S., Tang W.K., Lam V.K., Kwong S.L., et al. Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients. Pharmacopsychiatry 34 (2001) 238-241
85. Walle T., Byington R.P., Furberg C.D., McIntyre K.M., and Vokonas P.S. Biologic determinants of propranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack Trial. Clin Pharmacol Ther 38 (1985) 509-518
86. Walle T., Walle U.K., Cowart T.D., and Conradi E.C. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther 46 (1989) 257-263
87. Laine K., Tybring G., and Bertilsson L. No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin Pharmacol Ther 68 (2000) 151-159
88. Lucas D., Menez C., Girre C., Berthou F., Bodenez P., Joannet I., et al. Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics 5 (1995) 298-304
89. Kim R.B., and O'Shea D. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 57 (1995) 645-655
90. Bock K.W., Schrenk D., Forster A., Griese E.U., Morike K., Brockmeier D., et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 4 (1994) 209-218
91. Beierle I., Meibohm B., and Derendorf H. Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 37 (1999) 529-547
92. Court M.H., Duan S.X., von Moltke L.L., Greenblatt D.J., Patten C.J., Miners J.O., et al. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 299 (2001) 998-1006
93. Pacifici G.M., Evangelisti L., Giuliani L., Metelli R.M., and Giordani R. Zidovudine glucuronidation in human liver: interindividual variability. Int J Clin Pharmacol Ther 34 (1996) 329-334
94. Aksoy I.A., Sochorova V., and Weinshilboum R.M. Human liver dehydroepiandrosterone sulfotransferase: nature and extent of individual variation. Clin Pharmacol Ther 54 (1993) 498-506
95. Szumlanski C.L., Honchel R., Scott M.C., and Weinshilboum R.M. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 2 (1992) 148-159
96. Milano G., Etienne M.C., Cassuto-Viguier E., Thyss A., Santini J., Frenay M., et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol 10 (1992) 1171-1175
97. Zalcberg J., Kerr D., Seymour L., and Palmer M. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. Eur J Cancer 34 (1998) 1871-1875
98. Dobbs N.A., Twelves C.J., Gillies H., James C.A., Harper P.G., and Rubens R.D. Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 36 (1995) 473-476
99. Boudikova B., Szumlanski C., Maidak B., and Weinshilboum R. Human liver catechol-O-methyltransferase pharmacogenetics. Clin Pharmacol Ther 48 (1990) 381-389
100. Godfrey C., Sweeney K., Miller K., Hamilton R., and Kremer J. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br J Clin Pharmacol 46 (1998) 369-376
101. Gaudry S.E., Sitar D.S., Smyth D.D., McKenzie J.K., and Aoki F.Y. Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. Clin Pharmacol Ther 54 (1993) 23-27
102. Reyes J.L., Melendez E., Alegria A., and Jaramillo-Juarez F. Influence of sex differences on the renal secretion of organic anions. Endocrinology 139 (1998) 1581-1587
103. Kudo N., Suzuki E., Katakura M., Ohmori K., Noshiro R., and Kawashima Y. Comparison of the elimination between perfluorinated fatty acids with different carbon chain length in rats. Chem Biol Interact 134 (2001) 203-216
104. Kaasinen V., Nagren K., Hietala J., Farde L., and Rinne J.O. Sex differences in extrastriatal dopamine d(2)-like receptors in the human brain. Am J Psychiatry 158 (2001) 308-311
105. Fletcher C.V., Acosta E.P., and Strykowski J.M. Gender differences in human pharmacokinetics and pharmacodynamics. J Adolesc Health 15 (1994) 619-629
106. Jeste D.V., Lindamer L.A., Evans J., and Lacro J.P. Relationship of ethnicity and gender to schizophrenia and pharmacology of neuroleptics. Psychopharmacol Bull 32 (1996) 243-251
107. Barbui C., Nose M., Bindman J., Schene A., Becker T., Mazzi M.A., et al. Sex differences in the subjective tolerability of antipsychotic drugs. J Clin Psychopharmacol 25 (2005) 521-526
108. Cohen R.M., Nordahl T.E., Semple W.E., and Pickar D. The brain metabolic patterns of clozapine- and fluphenazine-treated female patients with schizophrenia: evidence of a sex effect. Neuropsychopharmacology 21 (1999) 632-640
109. Laakso A., Vilkman H., Bergman J., Haaparanta M., Solin O., Syvalahti E., et al. Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. Biol Psychiatry 52 (2002) 759-763
110. Dluzen D.E., and Ramirez V.D. In-vivo activity of the LH-releasing hormone pulse generator in castrated and intact male rats. J Endocrinol 107 (1985) 331-340
111. Shimizu H., and Bray G.A. Effects of castration, oestrogen replacement and estrus cycle on monoamine metabolism in the nucleus accumbens, measured by microdialysis. Brain Res 621 (1993) 200-206
112. Xiao L., and Becker J.B. Quantitative microdialysis determination of extracellular striatal dopamine concentration in male and female rats: effects of estrous cycle and gonadectomy. Neurosci Lett 180 (1994) 155-158
113. Dafny N., and Yang P.B. The role of age, genotype, sex, and route of acute and chronic administration of methylphenidate: a review of its locomotor effects. Brain Res Bull 68 (2006) 393-405
114. Kosten T.R., Kosten T.A., McDougle C.J., Hameedi F.A., McCance E.F., Rosen M.I., et al. Gender differences in response to intranasal cocaine administration to humans. Biol Psychiatry 39 (1996) 147-148
115. Munro C.A., McCaul M.E., Wong D.F., Oswald L.M., Zhou Y., Brasic J., et al. Sex differences in striatal dopamine release in healthy adults. Biol Psychiatry 59 (2006) 966-974
116. Sofuoglu M., Mitchell E., and Kosten T.R. Effects of progesterone treatment on cocaine responses in male and female cocaine users. Pharmacol Biochem Behav 78 (2004) 699-705
117. White T.L., Justice A.J., and de Wit H. Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol Biochem Behav 73 (2002) 729-741
118. Dluzen D.E., Tweed C., Anderson L.I., and Laping N.J. Gender differences in methamphetamine-induced mRNA associated with neurodegeneration in the mouse nigrostriatal dopaminergic system. Neuroendocrinology 77 (2003) 232-238
119. King D.E., Herning R.I., Gorelick D.A., and Cadet J.L. Gender differences in the EEG of abstinent cocaine abusers. Neuropsychobiology 42 (2000) 93-98
120. Pinto-Meza A., Usall J., Serrano-Blanco A., Suarez D., and Haro J.M. Gender differences in response to antidepressant treatment prescribed in primary care. Does menopause make a difference?. J Affect Disord 93 (2006) 53-60
121. Sagud M., Hotujac Lj., Mihaljevic-Peles A., and Jakovljevic M. Gender differences in depression. Coll Antropol 26 (2002) 149-157
122. Neumeister A. Tryptophan depletion, serotonin, and depression: where do we stand?. Psychopharmacol Bull 37 (2003) 99-115
123. Nishizawa S., Benkelfat C., Young S.N., Leyton M., Mzengeza S., de Montigny C., et al. Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci USA 94 (1997) 5308-5313
124. Bell C., Abrams J., and Nutt D. Tryptophan depletion and its implications for psychiatry. Br J Psychiatry 178 (2001) 399-405
125. Bano S., Akhter S., and Afridi M.I. Gender based response to fluoxetine hydrochloride medication in endogenous depression. J Coll Physicians Surg Pak 14 (2004) 161-165
126. Altshuler L.L., Bauer M., Frye M.A., Gitlin M.J., Mintz J., Szuba M.P., et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 158 (2001) 1617-1622
127. Kornstein S., Schatzberg A.F., Thase M.E., Yonkers K.A., McCullough J.P., Keitner G.I., et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 157 (2000) 1445-1452
128. Baca E., Garcia-Garcia M., and Porras-Chavarino A. Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 57-65
129. Khan A., Brodhead A.E., Schwartz K.A., Kolts R.L., and Brown W.A. Sex differences in antidepressant response in recent antidepressant clinical trials. J Clin Psychopharmacol 25 (2005) 318-324
130. Berlanga C., and Flores-Ramos M. Different gender response to serotoninergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. J Affect Disord 95 (2006) 119-123
131. Frackiewicz E.J., Sramek J.J., and Cutler N.R. Gender differences in depression and antidepressant pharmacokinetics and adverse events. Ann Pharmacother 34 (2000) 80-88
132. Hildebrandt M.G., Stage K.B., and Kragh-Soerensen P. Are gender differences important for the clinical effects of antidepressants?. Am J Psychiatry 160 (2003) 1643-1650
133. Quitkin F.M., Stewart J.W., McGrath P.J., Taylor B.P., Tisminetzky M.S., Petkova E., et al. Are there differences between women's and men's antidepressant responses?. Am J Psychiatry 159 (2002) 1848-1854
134. Parker G., Parker K., Austin M.P., Mitchell P., and Brotchie H. Gender differences in response to differing antidepressant drug classes: two negative studies. Psychol Med 33 (2003) 1473-1477
135. Wohlfarth T., Storosum J.G., Elferink A.J., van Zwieten B.J., Fouwels A., and van den Brink W. Response to tricyclic antidepressants: independent of gender?. Am J Psychiatry 161 (2004) 370-372
136. Thiels C., Linden M., Grieger F., and Leonard J. Gender differences in routine treatment of depressed outpatients with the selective serotonin reuptake inhibitor sertraline. Int Clin Psychopharmacol 20 (2005) 1-7
137. Viguera A.C., Tondo L., and Baldessarini R.J. Sex differences in response to lithium treatment. Am J Psychiatry 157 (2000) 1509-1511
138. Pigott T.A. Gender differences in the epidemiology and treatment of anxiety disorders. J Clin Psychiatry 60 (1999) 4-15
139. Pleym H., Spigset O., Kharasch E.D., and Dale O. Gender differences in drug effects: implications for anesthesiologists. Acta Anaesthesiol Scad 47 (2003) 241-259
140. Romano-Torres M., Borja-Lascurain E., Chao-Rebolledo C., del-Rio-Portilla Y., and Corsi-Cabrera M. Effect of diazepam on EEG power and coherent activity: sex differences. Psychoneuroendocrinology 27 (2002) 821-833
141. Gulinello M., and Smith S.S. Anxiogenic effects of neurosteroid exposure: sex differences and altered GABAA receptor pharmacology in adult rats. J Pharmacol Exp Ther 305 (2003) 541-548
142. Brambilla F., Mellado C., Alciati A., Pisu M.G., Purdy R.H., Zanone S., et al. Plasma concentrations of anxiolytic neuroactive steroids in men with panic disorder. Psychiatry Res 135 (2005) 185-190
143. Hoymork S.C., and Raeder J. Why do women wake up faster than men from propofol anaesthesia?. Br J Anaesth 95 (2005) 627-633
144. Gear R.W., Miaskowski C., Gordon N.C., Paul S.M., Heller P.H., and Levine J.D. Kappa-opioids produce significantly greater analgesia in women than in men. Nat Med 2 (1996) 1248-1250
145. Walker J.S., and Carmody J.J. Experimental pain in healthy human subjects: gender differences in nociception and in response to ibuprofen. Anesth Analg 86 (1998) 1257-1262
146. Lynch W.J., Roth M.E., and Carroll M.E. Biological basis of sex differences in drug abuse: preclinical and clinical studies. Psychopharmacology (Berl) 164 (2002) 121-137
147. Brady K.T., and Randall C.L. Gender differences in substance use disorders. Psychiatr Clin N Am 22 (1999) 241-252
148. Carroll M.E., Lynch W.J., Roth M.E., Morgan A.D., and Cosgrove K.P. Sex and oestrogen influence drug abuse. Trends Pharmacol Sci 25 (2004) 273-279
149. Liechti M.E., Gamma A., and Vollenweider F.X. Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl) 154 (2001) 161-168
150. Jochmann N., Stangl K., Garbe E., Baumann G., and Stangl V. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 26 (2005) 1585-1595
151. Sheifer S.E., Canos M.R., Weinfurt K.P., Arora U.K., Mendelsohn F.O., Gersh B.J., et al. Sex differences in coronary artery size assessed by intravascular ultrasound. Am Heart J 139 (2000) 649-653
152. Ridker P.M., Hennekens C.H., Rifai N., Buring J.E., and Manson J.E. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 100 (1999) 713-716
153. Cushman M., Legault C., Barrett-Connor E., Stefanick M.L., Kessler C., Judd H.L., et al. Effect of post-menopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 100 (1999) 717-722
154. Rossi M.L., Merlini P.A., and Ardissino D. Percutaneous coronary revascularisation in women. Thromb Res 103 (2001) S105-S111
155. Mosca L. Epidemiology and prevention of heart disease. In: Douglas P.S. (Ed). Cardiovascular health and disease in women (2002), WB Saunders, Philadelphia 23-28
156. Elsaesser A., and Hamm C.W. Acute coronary syndrome: the risk of being female. Circulation 109 (2004) 565-567
157. Antoniucci D., Miller V.M., Sieck G.C., and Fitzpatrick L.A. Gender-related differences in proliferative responses of vascular smooth muscle cells to endothelin-1. Endothelium 8 (2001) 137-145
158. Cross H.R., Murphy E., Koch W.J., and Steenbergen C. Male and female mice overexpressing the beta(2)-adrenergic receptor exhibit differences in ischemia/reperfusion injury: role of nitric oxide. Cardiovasc Res 53 (2002) 662-671
159. Leinwand L.A. Sex is a potent modifier of the cardiovascular system. J Clin Invest 112 (2003) 302-307
160. Mendelsohn M.E., and Karas R.H. Molecular and cellular basis of cardiovascular gender differences. Science 308 (2005) 1583-1587
161. Xin H.B., Senbonmatsu T., Cheng D.S., Wang Y.X., Copello J.A., Ji G.J., et al. Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy. Nature 416 (2002) 334-338
162. Janeway T.C. A clinical study of hypertensive cardiovascular disease. Arch Int Med 12 (1913) 755-798
163. Harris D.J., and Douglas P.S. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med 343 (2000) 475-480
164. Hinojosa-Laborde C., Chapa I., Lange D., and Haywood J.R. Gender differences in sympathetic nervous system regulation. Clin Exp Pharmacol Physiol 26 (1999) 122-126
165. Wing L.M., et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348 (2003) 583-592
166. Flather M.D., Yusuf S., Kober L., Pfeffer M., Hall A., Murray G., et al. Long term ACE-inhibitor therapy in patient with heart failure or left ventricular dysfunction: a systematic review of data from individual patients. Lancet 355 (2000) 1575-1581
167. Kimmelstiel C., and Goldberg R.J. Congestive heart failure in women: focus on heart failure due to coronary artery disease and diabetes. Cardiology 77 (1990) 71-79
168. Swedberg K., Held P., Kjekshus J., Rasmussen K., Ryden L., and Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 327 (1992) 678-684
169. The SOLVD Investigators. Gender differences in presentation, morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD): a preliminary report. In: Wenger N.K., Speroff L., and Packard B. (Eds). Cardiovascular health and disease in women (1993), Le Jacq Communications, Greenwich 345-348
170. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown Jr. E.J., Cuddy T.E., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 327 (1992) 669-677
171. Garg R., and Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality in patients with heart failure. JAMA 273 (1995) 1450-1456
172. Shekelle P.G., Rich M.W., Morton S.C., Atkinson C.S., Tu W., Maglione M., et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41 (2003) 1529-1538
173. Os I., Bratland B., Dahlof B., Gisholt K., Syvertsen J.O., and Tretli S. Female sex as an important determinant of lisinopril induced-cough. Lancet 339 (1992) 372
174. Walle T., Walle K., Mathur R.S., Palesch Y.Y., and Conradi E.C. Propranolol metabolism in normal subjects: association with sex steroid hormones. Clin Pharmacol Ther 56 (1994) 127-132
175. Luzier A.B., Killian A., Wilton J.H., Wilson M.F., Forrest A., and Kazierad D.J. Gender-related effects of metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 66 (1999) 594-601
176. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
177. Packer M., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 334 (2001) 1651-1658
178. Packer M., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106 (2002) 2194-2199
179. Simon T., Mary-Krause M., Funck-Brentano C., and Jaillon P. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation 103 (2001) 375-380
180. Ghali J.K., Pina I.L., Gottlieb S.S., Deedwania P.C., and Wikstrand J.C. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 105 (2002) 1585-1591
181. Rathore S.S., Wang Y., and Krumholz H.M. Sex based differences in the effect of digoxin in the treatment of heart failure. N Engl J Med 347 (2002) 1403-1411
182. Adams Jr. K.F., Patterson J.H., Gattis W.A., O'Connor C.M., Lee C.R., Schwartz T.A., et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol 46 (2005) 497-504
183. Sica D.A., Wood M., and Hess M. Gender and its effect in cardiovascular pharmacotherapeutics: recent considerations. Congest Heart Fail 11 (2005) 163-166
184. Kloner R.A., Sowers J.R., DiBona G.F., Gaffney M., and Wein M. Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. Am J Cardiol 77 (1996) 713-722
185. Chapman M.D., Hanrahan R., McEwen J., and Marley J.E. Hyponatremia and hypokalemia due to indapamide. Med J Aust 176 (2002) 219-221
186. Del Rio G., Verlardo A., Zizzo G., Marrama P., and Della Casa L. Sex differences in catecholamine response to clonidine. Int J Obes Relat Metab Disord 17 (1993) 465-469
187. Gong G., Johnson M.L., and Pettinger W.A. Testosterone regulation of renal alpha 2B-adrenergic receptor mRNA levels. Hypertension 25 (1995) 350-355
188. Cankar K., Finderle Z., and Strucl M. The role of α1 and α2 adrenoceptors in gender differences in cutaneous LD flux response to local cooling. Microvasc Res 68 (2004) 126-131
189. King D., Etzel J.P., Chopra S., Smith J., Cadman P.D., Rao F., et al. Human response to alpha-2-adrenergic agonist stimulation studied in an isolated vascular bed in vivo: biphasic influence of dose, age, gender, and receptor genotype. Clin Pharmacol Ther 77 (2005) 388-403
190. Jones S.B., Bylund D.B., Rieser C.A., Shekim W.O., Byer J.A., and Carr G.W. Alpha 2-adrenergic receptor binding in human platelets: alterations during the menstrual cycle. Clin Pharmacol Ther 34 (1983) 90-96
191. Kain K., Carter A.M., Bamford J.M., Grant P.J., and Catto A.J. Gender differences in coagulation and fibrinolysis in white subjects with acute ischemic stroke. J Thromb Haemost 1 (2003) 390-392
192. Haque S.F., Matsubayashi H., Izumi S., Sugi T., Arai T., Kondo A., et al. Sex difference in platelet aggregation detected by new aggregometry using light scattering. Endocr J 48 (2001) 33-41
193. Gurwitz J.H., Gore J.M., Goldberg R.J., Barron H.V., Breen T., Rundle A.C., et al. Risk for intracranial haemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in national registry of myocardial infarction 2. Ann Intern Med 129 (1998) 597-604
194. Becker R.C., Hochman J.S., Cannon C.P., Spencer F.A., Ball S.P., Rizzo M.J., et al. Fatal cardiac rupture among patient treated with thrombolytic agents and adjunctive thrombin antagonist: observation from Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study. J Am Coll Cardiol 33 (1999) 479-487
195. Van de Werf F. ASSENT-3: implication for future trial design and clinical practice. Eur Heart J 23 (2002) 911-912
196. Iakovou I., Dangas G., Mehran R., Lansky A.J., Kobayashi Y., Adamian M., et al. Gender difference in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors. Am J Cardiol 89 (2002) 976-979
197. Kent D.M., Price L.L., Ringleb P., Hill M.D., and Selker H.P. Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke. A pooled analysis of randomized clinical trials. Stroke 36 (2005) 62-65
198. Wyller T.B., Sodring K.M., Sveen U., Ljunggren A.E., and Bautz-Holter E. Are there gender differences in functional outcome after stroke?. Clin Rehabil 11 (1997) 171-179
199. Glader E.L., et al. Sex differences in management and outcome after stroke: a Swedish national perspective. Stroke 34 (2003) 1970-1975
200. Bushnell C.D., Griffin J., Newby L.K., Goldstein L.B., Mahaffey K.W., Graffagnino C.A., et al. Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke 37 (2006) 1427-1431
201. Becker D.M., Segal J., Vaidya D., Yanek L.R., Herrera-Galeano J.E., Bray P.F., et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 295 (2006) 1420-1427
202. Ridker P.M., Cook N.R., Lee I.M., Gordon D., Gaziano J.M., Manson J.E., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005) 1293-1304
203. Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm H., Welsh P.A., Brooks L., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
204. Nguyen V., and McLaughlin M. Coronary artery disease in women: a review of emerging cardiovascular risk factors. Mt Sinai J Med 69 (2002) 338-349
205. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
206. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
207. Woods S.C., Gotoh K., and Clegg D.J. Gender differences in the control of energy homeostasis. Exp Biol Med (Maywood) 228 (2003) 1175-1180
208. Borissova A.M., Tankova T., Kirilov G., and Koev D. Gender-dependent effect of ageing on peripheral insulin action. Int J Clin Pract 59 (2005) 422-426
209. Nuutila P., Maki M., Laine H., Knuuti M.J., Ruotsalainen U., Luotolahti M., et al. Insulin action on heart and skeletal muscle glucose uptake in essential hypertension. J Clin Invest 96 (1995) 1003-1009
210. Hokanson J.E., and Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3 (1996) 213-219
211. Yoon M., Jeong S., Nicol C.J., Lee H., Han M., Kim J.J., et al. Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism. Exp Mol Med 34 (2002) 481-488
212. Jalouli M., Carlsson L., Ameen C., Linden D., Ljungberg A., Michalik L., et al. Sex difference in hepatic peroxisome proliferator-activated receptor alpha expression: influence of pituitary and gonadal hormones. Endocrinology 144 (2003) 101-109
213. Tai E.S., bin Ali A., Zhang Q., Loh L.M., Tan C.E., Retnam L., et al. Hepatic expression of PPARalpha, a molecular target of fibrates, is regulated during inflammation in a gender-specific manner. FEBS Lett 546 (2003) 237-240
214. Kajinami K., Brousseau M.E., Lamon-Fava S., Ordovas J.M., and Schaefer E.J. Gender-specific effects of oestrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism. Atherosclerosis 178 (2005) 331-338
215. Angele M.K., Wichmann M.W., Ayala A., Cioffi W.G., and Chaudry I.H. Testosterone receptor blockade after hemorrhage in males. Restoration of the depressed immune functions and improved survival following subsequent sepsis. Arch Surg 132 (1997) 1207-1214
216. Angele M.K., Ayala A., Monfils B.A., Cioffi W.G., Bland K.I., and Chaudry I.H. Testosterone and/or low estradiol: normally required but harmful immunologically for males after trauma-hemorrhage. J Trauma 44 (1998) 78-85
217. Angele M.K., Schwacha M.G., Ayala A., and Chaudry I.H. Effect of gender and sex hormones on immune responses following shock. Shock 14 (2000) 81-90
218. Diodato M.D., Knoferl M.W., Schwacha M.G., Bland K.I., and Chaudry I.H. Gender differences in the inflammatory response and survival following haemorrhage and subsequent sepsis. Cytokine 14 (2001) 162-169
219. Losonczy G., Kriston T., Szabo A., Muller V., Harvey J., Hamar P., et al. Male gender predisposes to development of endotoxic shock in the rat. Cardiovasc Res 47 (2000) 183-191
220. Wichmann M.W., Ayala A., and Chaudry I.H. Male sex steroids are responsible for depressing macrophage immune function after trauma-hemorrhage. Am J Physiol 273 (1997) C1335-C1340
221. Shames R.S. Gender differences in the development, function of the immune system. J Adolesc Health 30 (2002) 59-70
222. Troisi R.J., Speizer F.E., Willett W.C., Trichopoulos D., and Rosner B. Menopause, postmenopausal oestrogen preparations, and the risk of adult-onset asthma. A prospective cohort study. Am J Respir Crit Care Med 152 (1995) 1183-1188
223. Inoue S., Yamada Y., Kuzuhara K., Ubara Y., Hara S., and Ootubo O. Are women privileged organ recipients?. Transplantat Proc 34 (2002) 2775-2776
224. Min D.I., Lee M., Ku Y.M., and Flanigan M. Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. Clin Pharmacol Ther 68 (2000) 478-486
225. Erben R.G., Brunner K.S., Breig B., Eberle J., Goldberg M., and Hofbauer L.C. Skeletal effects of cyclosporin A are gender related in rats. Endocrinology 144 (2003) 40-49
226. Enosawa S., and Hirasawa K. Sex-associated differences in the survival of skin grafts in rats. Enhancement of cyclosporine immunosuppression in male compared with female recipients. Transplantation 47 (1989) 933-937
227. Ofotokun I. Sex differences in the pharmacological effects of antiretroviral drugs: potential role of drug transporters and phase 1 and 2 metabolizing enzymes. Top HIV Med 13 (2005) 79-83
228. Fletcher C.V., Jiang H., Brundage R.C., Acosta E.P., Haubrich R., Katzenstein D., et al. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis 189 (2004) 1176-1184
229. Pai M.P., Schriever C.A., Diaz-Linares M., Novak R.M., and Rodvold K.A. Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1. Pharmacotherapy 24 (2004) 592-599
230. Fattinger K., Roos M., Vergeres P., Holenstein C., Kind B., Masche U., et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss department of internal medicine. Br J Clin Pharmacol 49 (2000) 158-167
231. Hurwitz N. Predisposing factors in adverse reactions to drugs. Br Med J 1 (1969) 536-539
232. Domecq C., Naranjo C.A., Ruiz I., and Busto U. Sex-related variations in the frequency and characteristics of adverse drug reactions. Int J Clin Pharmacol Ther Toxicol 18 (1980) 362-366
233. Lazarou J., Pomeranz B.H., and Corey P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279 (1998) 1200-1205
234. Martin R.M., Biswas P.N., Freemantle S.N., Pearce G.L., and Mann R.D. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol 46 (1998) 505-511
235. Women's Health. GAO report to Congressional Requesters 01-754; July 2001.
236. Owens Jr. R.C. QT prolongation with antimicrobial agents: understanding the significance. Drugs 64 (2004) 1091-1124
237. Roden D.M. Drug induced prolongation of the QT interval. N Engl J Med 350 (2004) 1013-1022
238. Drici M.D., and Clement N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 24 (2001) 575-585
239. Liu X.K., Katchman A., Drici M.D., Ebert S.N., Ducic I., Morad M., et al. Gender difference in the cycle length-dependent QT and potassium currents in rabbits. J Pharmacol Exp Ther 285 (1998) 672-679
240. Rodriquez I., Kilborn M.J., Liu X.K., Pezzullo J.C., and Woosley R.L. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 285 (2001) 1322-1326
241. Naqvi T.Z., and Gross S.B. Anorexigen-induced cardiac valvulopathy and female gender. Curr Womens Health Rep 3 (2003) 116-125
242. Montastruc J.L., Lapeyre-Mestre M., Bagheri H., and Fooladi A. Gender differences in adverse drug reactions: analysis of spontaneous reports to a Regional Pharmacovigilance Centre in France. Fundam Clin Pharmacol 16 (2002) 343-346
243. Ostapowicz G., et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137 (2002) 947-954
244. Neutel C.I., Maxwell C.J., and Appel W.C. Differences between males and females in risk of NSAID-related severe gastrointestinal events. Pharmacoepidemiol Drug Saf 8 (1999) 501-507
245. Warnock J.K., and Morris D.W. Adverse cutaneous reactions to antidepressants. Am J Clin Dermatol 3 (2002) 329-339
246. Fleisch J., Fleisch M.C., and Thürmann P.A. Women in early-phase clinical drug trials: have things changed over the past 20 years?. Clin Pharmacol Ther 78 (2005) 445-452